GB201102913D0 - Novel therapeutic - Google Patents

Novel therapeutic

Info

Publication number: GB201102913D0
Authority: GB; United Kingdom
Prior art keywords: novel therapeutic; therapeutic; novel
Prior art date: 2011-02-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB1102913.9A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Birmingham

Original Assignee

University of Birmingham

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-18

Filing date

2011-02-18

Publication date

2011-04-06

2011-02-18 Application filed by University of Birmingham filed Critical University of Birmingham

2011-02-18 Priority to GBGB1102913.9A priority Critical patent/GB201102913D0/en

2011-04-06 Publication of GB201102913D0 publication Critical patent/GB201102913D0/en

2012-02-17 Priority to PCT/GB2012/000167 priority patent/WO2012110768A1/en

Status Ceased legal-status Critical Current

Links

230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

GBGB1102913.9A 2011-02-18 2011-02-18 Novel therapeutic Ceased GB201102913D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB1102913.9A GB201102913D0 (en)	2011-02-18	2011-02-18	Novel therapeutic
PCT/GB2012/000167 WO2012110768A1 (en)	2011-02-18	2012-02-17	Therapeutic uses of diarylalkanes such as mitotane

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1102913.9A GB201102913D0 (en)	2011-02-18	2011-02-18	Novel therapeutic

Publications (1)

Publication Number	Publication Date
GB201102913D0 true GB201102913D0 (en)	2011-04-06

Family

ID=43881376

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB1102913.9A Ceased GB201102913D0 (en)	2011-02-18	2011-02-18	Novel therapeutic

Country Status (2)

Country	Link
GB (1)	GB201102913D0 (en)
WO (1)	WO2012110768A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111830169B (en) *	2020-07-24	2022-07-12	中山大学	Compounds and applications for the diagnosis of polycystic ovary syndrome

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4146648A (en) *	1977-07-14	1979-03-27	Bristol-Myers Company	Chemotherapeutic composition
AU627466B2 (en)	1988-05-25	1992-08-27	Smithkline Beckman Corporation	Aromatic steroid 5-alpha-reductase inhibitors
WO1993013124A1 (en)	1991-12-20	1993-07-08	Glaxo Inc.	Inhibitors of 5-alpha-testosterone reductase
GB9204024D0 (en)	1992-02-25	1992-04-08	Fujisawa Pharmaceutical Co	Indole derivatives
GB9204365D0 (en)	1992-02-28	1992-04-08	Pfizer Ltd	Indoles
ATE195129T1 (en)	1992-05-20	2000-08-15	Merck & Co Inc	4-AZASTEROIDS AS 5-ALPHA-REDUCTASE
GB9213835D0 (en)	1992-06-30	1992-08-12	Smithkline Beecham Corp	Compounds
GB9213901D0 (en)	1992-06-30	1992-08-12	Smithkline Beecham Corp	Compounds
IL107611A0 (en)	1992-11-18	1994-02-27	Smithkline Beecham Corp	Steroid compounds and pharmaceutical compositions containing them
GB9302577D0 (en)	1993-02-10	1993-03-24	Fujisawa Pharmaceutical Co	Indole derivatives
WO1994022821A1 (en)	1993-04-05	1994-10-13	Fujisawa Pharmaceutical Co., Ltd.	Indole derivatives as testosterone 5 alpha-reductase inhibitors
GB9317096D0 (en)	1993-08-17	1993-09-29	Pfizer Ltd	Indoles
TW382595B (en)	1993-10-15	2000-02-21	Merck & Co Inc	Pharmaceutical composition for use in arresting and reversing androgenic alopecia
BR9407866A (en)	1993-10-21	1996-10-29	Merck & Co Inc	Composed processes for inhibiting 5-reductase or isoenzymes of the same treatment for acne conditions vulgar androgenic alopecia female hirsutism benign prostatic hyperplasia prostatitis and for the treatment and / or prevention of prostate cancer to stop and reverse androgenic alopecia and promoting the growth of androgenic alopecia hair in a mammal and for inhibiting the biosynthetic conversion of testosterone to dihydro-testosterone in a mammal and pharmaceutical composition
EP0748221B1 (en)	1993-11-04	1999-04-14	Merck & Co. Inc.	7-substituted-4-aza-steroid derivatives as 5-alpha- reductase inhibitors
IL111467A0 (en)	1993-11-12	1994-12-29	Merck & Co Inc	Pharmaceutical compositions comprising 7 beta -substituted -4-aza 5 alpha -cholestan-3-ones and 5 alpha reductase 1 inhibitors
GB9402041D0 (en)	1994-02-03	1994-03-30	Smithkline Beecham Corp	Compounds
GB9403516D0 (en)	1994-02-24	1994-04-13	Pfizer Ltd	Indoles
GB9409583D0 (en)	1994-05-13	1994-07-06	Pfizer Ltd	Indoles
US5578724A (en)	1994-09-20	1996-11-26	Eli Lilly And Company	Process for preparation of benzo[f]quinolinones
WO1997011702A1 (en)	1995-09-27	1997-04-03	Merck & Co., Inc.	Method of preventing androgenetic alopecia with 5-alpha reductase inhibitors
EP0862436A1 (en)	1995-10-19	1998-09-09	Merck & Co., Inc.	16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
JP2000505444A (en)	1996-02-14	2000-05-09	ヘキスト・マリオン・ルセル・インコーポレイテツド	17β-cyclopropyl (amino / oxy) 4-azasteroid as an inhibitor of the activity of testosterone 5α-reductase and C lower 17-20 lyase
JP2001523259A (en)	1997-05-07	2001-11-20	ノヴォファームリミテッド	4-aza-steroids
GB0001449D0 (en) *	2000-01-21	2000-03-08	Cortendo Ab	Compositions
WO2002000681A1 (en)	2000-06-27	2002-01-03	Aventis Pharma S.A.	20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
US20050182105A1 (en) *	2004-02-04	2005-08-18	Nirschl Alexandra A.	Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
GB0902565D0 (en) *	2009-02-16	2009-04-01	Alta Innovations Ltd	Assay

2011
- 2011-02-18 GB GBGB1102913.9A patent/GB201102913D0/en not_active Ceased
2012
- 2012-02-17 WO PCT/GB2012/000167 patent/WO2012110768A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO2012110768A1 (en)	2012-08-23

Legal Events

Date	Code	Title	Description
2012-10-10	AT	Applications terminated before publication under section 16(1)

Publication	Publication Date	Title
ZA201305897B (en)	2014-04-30	Combination therapy
IL229254A0 (en)	2014-01-30	Therapeutic antibodies
IL233756A0 (en)	2014-09-30	Novel therapeutic agents
GB201114212D0 (en)	2011-10-05	Therapeutic agents
ZA201400120B (en)	2015-09-30	Combination therapy
GB201119401D0 (en)	2011-12-21	Therapeutic agents
PT2783256T (en)	2022-01-24	Therapeutic eyewear
EP2709661A4 (en)	2015-01-28	Therapeutic anti-igf1r combinations
ZA201502595B (en)	2017-01-25	Therapeutic methods
EP2701744A4 (en)	2014-08-20	Combination therapy
GB201119167D0 (en)	2011-12-21	Novel bachteriophages
EP2704731A4 (en)	2015-02-11	Avian-based treatment
GB201102913D0 (en)	2011-04-06	Novel therapeutic
GB201120096D0 (en)	2012-01-04	Novel therapy
GB201110895D0 (en)	2011-08-10	Therapeutic use
GB201114226D0 (en)	2011-10-05	Combination therapy
GB201101128D0 (en)	2011-03-09	Therapeutic agents
GB201115558D0 (en)	2011-10-26	Therapeutic agents
GB201110614D0 (en)	2011-08-03	Therapeutic agents
ZA201405764B (en)	2017-09-27	Novel therapeutic agents
ZA201308992B (en)	2021-05-26	Therapeutic antibodies
GB201107854D0 (en)	2011-06-22	Novel 5-hydroxy-5-aryl-pyrrol-2-ones
GB201108947D0 (en)	2011-07-13	Novel use
GB201103770D0 (en)	2011-04-20	Novel use
GB201102266D0 (en)	2011-03-23	Treatment